Perceptive Xontogeny Venture Fund Leads $44M Investment in CereVasc

Choate represented Perceptive Xontogeny Venture Fund as the lead investor in the $44M Series A investment in CereVasc, a company focused on improving the treatment of patients with hydrocephalus. CereVasc is currently developing the eShunt™ System, the first minimally invasive cerebrospinal fluid shunt and delivery technology designed to avoid the need for invasive surgery and extended hospitalization associated with the current surgical treatment of hydrocephalus. This investment will support the first-in-human clinical trial of the eShunt™ System, as well as follow-on clinical studies to support regulatory approvals. The first study is expected to begin enrollment during the second half of 2020.